Glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson's disease

Takao Yasuhara, Tetsuro Shingo, Isao Date

Research output: Contribution to journalReview articlepeer-review

39 Citations (Scopus)


Many studies using animals clarify that glial cell line-derived neurotrophic factor (GDNF) has strong neuroprotective and neurorestorative effects on dopaminergic neurons. Several pilot studies clarified the validity of continuous intraputaminal GDNF infusion to patients with Parkinson's disease (PD), although a randomized controlled trial of GDNF therapy published in 2006 resulted in negative outcomes, and controversy remains about the efficacy and safety of the treatment. For a decade, our laboratory has investigated the efficacy and the most appropriate method of GDNF administration using animals, and consequently we have obtained some solid data that correspond to the results of clinical trials. In this review, we present an outline of our studies and other key studies related to GDNF, the current state of the research, problems to be overcome, and predictions regarding the use of GDNF therapy for PD in the future. Copyright

Original languageEnglish
Pages (from-to)51-56
Number of pages6
JournalActa medica Okayama
Issue number2
Publication statusPublished - Apr 2007


  • Cell transplantation
  • Clinical trial
  • Encapsulation
  • Gene therapy
  • Neurodegenerative disease

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson's disease'. Together they form a unique fingerprint.

Cite this